Molecular markers for incidence, prognosis, and response to therapy.

Published

Journal Article

Lung cancer is the most common malignancy in the United States and worldwide. In 2011, it is estimated that more than 221,000 people in the United States will be diagnosed with cancer of the lung and bronchus. For patients with early-stage disease, 5-year survival approaches only 50%. Recent advances using molecular, genetic, and proteomic profiling of lung tumors have enabled refining the prognosis for patients with non-small cell lung cancer. With targeted therapies, there is an opportunity to enhance long-term survival. This article discusses several key molecular markers used in the prognostication and treatment of non-small cell lung cancer.

Full Text

Duke Authors

Cited Authors

  • Tong, BC; Harpole, DH

Published Date

  • January 2012

Published In

Volume / Issue

  • 21 / 1

Start / End Page

  • 161 - 175

PubMed ID

  • 22098838

Pubmed Central ID

  • 22098838

Electronic International Standard Serial Number (EISSN)

  • 1558-5042

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2011.09.007

Language

  • eng

Conference Location

  • United States